collection
MENU ▼
Read by QxMD icon Read
search

Depression

shared collection
9 papers 1000+ followers
By Faye Kehler Family Physician and GP Anesthetist since 1987 interested in all aspects of Medicine
https://www.readbyqxmd.com/read/28749092/ketamine-for-depression-4-in-what-dose-at-what-rate-by-what-route-for-how-long-and-at-what-frequency
#1
REVIEW
Chittaranjan Andrade
BACKGROUND: Ketamine, administered in subanesthetic doses, is an effective off-label treatment for severe and even treatment-refractory depression; however, despite dozens of studies across nearly 2 decades of research, there is no definitive guidance on matters related to core practice issues. METHODS: This article presents a qualitative review and summary about what is known about ketamine dosing, rate of administration, route of administration, duration of treatment, and frequency of sessions...
July 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28448702/ketamine-for-depression-1-clinical-summary-of-issues-related-to-efficacy-adverse-effects-and-mechanism-of-action
#2
REVIEW
Chittaranjan Andrade
Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from conventional antidepressant drugs in that it brings about rapid and marked attenuation of depressive symptoms even in patients with refractory depression...
April 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28570803/ketamine-for-depression-2-diagnostic-and-contextual-indications
#3
REVIEW
Chittaranjan Andrade
There is a substantial body of literature comprising anecdotal material and descriptions of uncontrolled and randomized controlled trials addressing the use of subanesthetic doses of ketamine for the off-label treatment of major depressive episodes. This article examines diagnostic indications for the off-label use of ketamine as an antidepressant and possible contexts in which ketamine may be trialled. Ketamine is indicated in patients who are in a major depressive episode. Most of the research data have been collected from patients with major depressive disorder, but patients with bipolar depression have also been studied...
May 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26926124/a-new-option-for-treating-bipolar-i-depression
#4
EDITORIAL
Holly A Swartz, Joseph T Tasosa
No abstract text is available yet for this article.
March 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26765254/why-we-need-a-transdiagnostic-staging-approach-to-emerging-psychopathology-early-diagnosis-and-treatment
#5
EDITORIAL
Patrick McGorry, Barnaby Nelson
No abstract text is available yet for this article.
March 2016: JAMA Psychiatry
https://www.readbyqxmd.com/read/26643054/royal-australian-and-new-zealand-college-of-psychiatrists-clinical-practice-guidelines-for-mood-disorders
#6
REVIEW
Gin S Malhi, Darryl Bassett, Philip Boyce, Richard Bryant, Paul B Fitzgerald, Kristina Fritz, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard Porter, Ajeet B Singh
OBJECTIVES: To provide guidance for the management of mood disorders, based on scientific evidence supplemented by expert clinical consensus and formulate recommendations to maximise clinical salience and utility. METHODS: Articles and information sourced from search engines including PubMed and EMBASE, MEDLINE, PsycINFO and Google Scholar were supplemented by literature known to the mood disorders committee (MDC) (e.g., books, book chapters and government reports) and from published depression and bipolar disorder guidelines...
December 2015: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/25744620/antidepressants-and-the-adolescent-brain
#7
REVIEW
Lesley Cousins, Ian M Goodyer
Major unipolar depression is a significant global health problem, with the highest incident risk being during adolescence. A depressive illness during this period is associated with negative long-term consequences including suicide, additional psychiatric comorbidity, interpersonal relationship problems, poor educational performance and poor employment attainment well into adult life. Despite previous safety concerns, selective serotonin reuptake inhibitors (SSRIs) remain a key component of the treatment of moderate to severe depression episodes in adolescents...
May 2015: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/25354101/antidepressants-black-box-warning-10-years-later
#8
Richard A Friedman
In 2004, the Food and Drug Administration (FDA) issued a black-box warning on antidepressants indicating that they were associated with an increased risk of suicidal thinking, feeling, and behavior in young people. The agency's decision was immediately controversial: many members of the medical..
October 30, 2014: New England Journal of Medicine
https://www.readbyqxmd.com/read/25243608/antidepressant-dosage-and-suicidal-ideation
#9
COMMENT
Philippe Courtet, Jorge Lopez-Castroman, Isabelle Jaussent, Philip A P M Gorwood
No abstract text is available yet for this article.
November 2014: JAMA Internal Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"